Alterations in two oncogenic drivers: Impact of concurrent PIK3CA or AKT1 mutations in patients with oncogene-driven lung adenocarcinomas.
Juliana Eng
No relevant relationships to disclose
Matthew David Hellmann
No relevant relationships to disclose
Kaitlin Woo
No relevant relationships to disclose
Camelia S. Sima
No relevant relationships to disclose
Helena Alexandra Yu
No relevant relationships to disclose
Maria E. Arcila
No relevant relationships to disclose
Marc Ladanyi
No relevant relationships to disclose
Mark G. Kris
Consultant or Advisory Role - AstraZeneca; Exelixis; Novartis; Pfizer; Roche/Genentech
Research Funding - Boehringer Ingelheim; Pfizer; Puma Biotechnology
Alexander E. Drilon
No relevant relationships to disclose